CorMedix's $222.6M Heron Deal Buys a Four-Product Hospital Pain and Nausea Portfolio
CorMedix will acquire substantially all of Heron Therapeutics' assets, a hospital-focused portfolio, as small-cap biotechs elsewhere sell assets, license in or seek buyers.
What happened
CorMedix has agreed to buy substantially all of Heron Therapeutics' assets in a deal worth about $222.6M upfront. The package includes four hospital-use products for postoperative pain and for nausea and vomiting. Closing is expected in the first quarter of 2027.
The structure matters. This is an asset purchase, not a merger of equals or a tender for shares. CorMedix takes the commercial portfolio, and the Heron corporate entity is left to be dealt with separately. The material we have does not say what happens to that entity, whether further consideration beyond the upfront payment is due, or how CorMedix will fund the purchase. Those gaps will shape how the deal is judged once filings land.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- CorMedix to acquire Heron Therapeutics' assets in deal worth about $222.6M upfront Heron Therapeutics, Inc. /De/ · 09 Nov 2026
- MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first Macrogenics Inc · 13 Nov 2026
- Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient Xenetic Biosciences, Inc. · 13 Nov 2026
- Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review Longeveron Inc. · 12 Nov 2026
- Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage Silence Therapeutics plc · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.
Vir's Follow-On Tests Whether Open Equity Windows Favor Platform Stories Over Small-Cap Fixes
Vir Biotechnology's unpriced offering lands the same week as a $225M Windward IPO and a string of warrant-laden small-cap raises, showing how differently capital is available across biotech.
Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question
The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.
IM Cannabis funds a shrinking business with converts while peers raise on scale and strategics
IM Cannabis's nine-month loss and shareholders' deficit sit against a week of financings in which strategic capital and clinical catalysts, not survival needs, set the terms.